GW 766994

Modify Date: 2024-01-06 10:47:49

Use of GW 766994

GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.

Name	GW-766994
Synonym	More Synonyms

Description	GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.
Related Catalog	Research Areas >> Inflammation/Immunology
Target	CCR3:7.86 (pKi)
In Vitro	GW 766994 is a specific chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis[1]. GW 766994 (10 μM) reverses CCL11-induced activation of CDK5, phosphorylations of CDK5, GSK3β, and increased phosphorylation of tau in hippocampal neurons[2].
References	[1]. Neighbour H, et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014 Apr;44(4):508-16. [2]. Zhu C, et al. Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2017 Dec;54(10):7964-7978.

4-{[({[(2S)-4-(3,4-Dichlorobenzyl)-2-morpholinyl]methyl}carbamoyl)amino]methyl}benzamide

Z6213K1TPE

Benzamide, 4-[[[[[[(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl]methyl]amino]carbonyl]amino]methyl]-

GW-766994

Get all suppliers and price by the below link: